Key Highlights

  • LTR Pharma's first U.S. ROXUS prescriptions were fulfilled on 6 October 2026, and the company held A$18.2 million in cash.
  • Entropy Neurodynamics reported 100% clinically meaningful response and 50% remission at 12 weeks among six binge eating disorder patients.
  • Vitrafy's executed U.S. partnerships cover about 17% of civilian blood collection sites, and it held A$38.3 million in cash and term deposits.
  • Net operating cash outflows for the quarter were A$1.6 million for LTR Pharma, $1.8 million for Entropy and A$4.9 million for Vitrafy.

LTR Pharma Limited (ASX:LTP), Entropy Neurodynamics Limited (ASX:ENP) and Vitrafy Life Sciences Limited (ASX:VFY) each filed quarterly activities reports and Appendix 4C statements on 28 October 2026. LTR Pharma reported the first fulfilled U.S. prescriptions for ROXUS, Entropy released 12-week binge eating disorder data for TRP-8803, and Vitrafy added two partners for its Guardion cryopreservation device. The figures below are taken from each company's own report.

LTR Pharma: ROXUS Prescriptions and SPONTAN Data

Following definitive agreements with Shed Holdings on 17 July and Strive Specialties on 20 July 2026, the first patient-specific ROXUS prescriptions were fulfilled in the United States on 6 October. The final SPONTAN Phase II report showed a median Tmax of 10 minutes for the 5 mg spray against 60 minutes for oral vardenafil 20 mg (p<0.0001) among 27 participants, with no serious adverse events. A 147-patient real-world study recorded a 68% composite response overall, 93% among men seeking greater convenience and spontaneity and 64% in the post-prostatectomy subgroup. Ethics approval was also received on 22 October for an investigator-initiated pulmonary arterial hypertension study led by Professor David Celermajer. More than 2,000 bottles had been dispensed in Australia by 20 October. The company held A$18.2 million in cash with no debt.

Entropy Neurodynamics: TRP-8803 Across Multiple Indications

All six Cohort 1 patients, who had binge eating disorder for a median of 15 years, kept a clinically meaningful improvement at 12 weeks. Three of them recorded no binge-eating episodes over 84 days, and weekly episodes were 73% below baseline. Ethics approval covers a Phase 1b/2a basket study of up to 72 patients across eight indications. Weekly binge-eating episodes were 74% lower at four weeks, and the shortened 60-minute infusion in Cohort 2 began after quarter end, with topline results expected by the end of calendar 2026. Entropy also signed a pre-Clinical Trial Agreement with UCSF for a US Phase 2 trial against escitalopram in up to 80 young adults, and a manufacturing agreement with BioCina. Cash and equivalents were $3.626 million, with total available funding of $6.225 million including a $2.6 million loan facility.

Vitrafy: Blood Partnerships and Device Builds

Vitrafy signed Versiti Blood Health on 30 September, joining Vitalant and Hoxworth Blood Center, and Charter Medical on 2 September for cell and gene therapy. The three blood partnerships cover about 179 fixed-point collection sites that collect roughly 2.4 million units a year. Nine Guardion devices were built in the quarter, with six more due in the first half of FY2027, and U.S. medical device listing is expected by the end of that half. The USAISR presented platelet results at the AABB meeting in Atlanta reporting 94.4% mean post-thaw recovery. Net operating cash outflow was A$4.9 million, and cash and term deposits totalled A$38.3 million, equal to 7.9 estimated quarters of funding when the deposits are included.

Side-by-Side Figures From the Three Reports

Set against each other, the reports show different stages of activity. LTR Pharma had product in patients' hands in both Australia and the United States and recorded customer receipts of A$366,035. Entropy, which had no customer receipts, spent $849,000 on research and development and expects a $2 million R&D Tax Incentive refund in the current quarter. Vitrafy recorded customer receipts of A$113,000. Related party payments were A$329,280 for LTR Pharma, $258,000 for Entropy and A$214,000 for Vitrafy. Net operating cash outflows were A$1.6 million for LTR Pharma, $1.8 million for Entropy, up from $1.4 million in the June quarter, and A$4.9 million for Vitrafy. Cash positions at 30 September were A$18.2 million, about $6.2 million in cash and facilities, and A$38.3 million respectively.